POTELIGEO Treatment in Patients with Relapsed or Refractory Mycosis Fungoides (MF) or Sezary Syndrome (SS) After at Least one Prior Systemic Therapy

The main puropose of the expanded access program is to facilitate access to POTELIGEO for patients who lack therapeutic alternatives and in which there is a reasonable expectation that the provision of access to POTELIGEO will have a positive benefit/risk for the patient during the time between commercial approval by the FDA and the date of availability of commercial supply to patients. Permission to use this investigational drug by the FDA is limited to our one single patient.

You may be eligible for this study if you meet the following criteria:

• Conditions: TBD
• Age: 99 years or below
• Gender: All